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ABSTRACT
Objective To systematically review the evidence that
smoking cessation after diagnosis of a primary lung
tumour affects prognosis.
Design Systematic review with meta-analysis.
Data sources CINAHL (from 1981), Embase (from 1980),
Medline (from 1966), Web of Science (from 1966),
CENTRAL (from 1977) to December 2008, and reference
lists of included studies.
Study selection Randomised controlled trials or
observational longitudinal studies that measured the
effect of quitting smoking after diagnosis of lung cancer
on prognostic outcomes, regardless of stage at
presentation or tumour histology, were included.
DataextractionTworesearchersindependentlyidentified
studies for inclusion and extracted data. Estimates were
combined by using a random effects model, and the I
2
statistic was used to examine heterogeneity. Life tables
were used to model five year survival for early stage non-
small cell lung cancer and limited stage small cell lung
cancer, using death rates for continuing smokers and
quitters obtained from this review.
Results In 9/10 included studies, most patients studied
were diagnosed as having an early stage lung tumour.
Continued smoking was associated with a significantly
increased risk of all cause mortality (hazard ratio 2.94,
95% confidence interval 1.15 to 7.54) and recurrence
(1.86, 1.01 to 3.41) in early stage non-small cell lung
cancer and of all cause mortality (1.86, 1.33 to 2.59),
development of a second primary tumour (4.31, 1.09 to
16.98), and recurrence (1.26, 1.06 to 1.50) in limited
stage small cell lung cancer. No study contained data on
the effect of quittingsmoking on cancerspecific mortality
or on development of a second primary tumour in non-
smallcelllungcancer.Lifetablemodellingonthebasisof
thesedataestimated33%fiveyearsurvivalin65yearold
patients with early stage non-small cell lung cancer who
continued to smoke compared with 70% in those who
quit smoking. In limited stage small cell lung cancer, an
estimated 29% of continuing smokers would survive for
five years compared with 63% of quitters on the basis of
the data from this review.
Conclusions This review provides preliminary evidence
thatsmokingcessationafterdiagnosisofearlystagelung
cancer improves prognostic outcomes. From life table
modelling, the estimated number of deaths prevented is
larger than would be expected from reduction of
cardiorespiratory deaths after smoking cessation, so
most of the mortality gain is likely to be due to reduced
cancer progression. These findings indicate that offering
smoking cessation treatment to patients presenting with
early stage lung cancer may be beneficial.
INTRODUCTION
Worldwide, lung cancer is the most commonly diag-
nosed form of cancer.
1 In the United Kingdom, its
annual incidence is second only to that of breast can-
cer, accounting for around 39000 new cancer diag-
noses annually.
2 In countries that have seen a high
prevalence of smoking, around 90% of diagnoses of
lung cancer are attributable to cigarette smoking.
3
Theincreasedincidencefromsmokingisproportional
to the length and intensity of smoking history.
4 On
average, a lifetime smoker has a 20-fold increase in
the risk of developing lung cancer compared with a
lifetime non-smoker.
1 Lung cancer is more common
in men than in women, closely following past patterns
ofsmokingprevalence,and80%ofcasesarediagnosed
in people aged over 60.
2
Smoking cessation before diagnosis reduces the risk
of developing a primary tumour of all major histologi-
cal types of lung carcinoma; the greatest reduction is
seen in small cell and squamous cell tumours.
5 How-
ever, whether smoking cessation after diagnosis of a
lung tumour can improve survival rates is less clear.
Thebiologicalmechanismsbywhichtoxinsintobacco
smoke cause lung cancer are complex and still not
completely understood, but carcinogens in tobacco
smoke may not only act as genetic inducers but also
act to promote progression of the disease.
67 As well
as potentially reducing the risk of cancer related mor-
bidity and mortality, quitting smoking at diagnosis
could reduce overall mortality, as smoking cessation
reducesmortalityfromotherdiseasessuchasheartdis-
ease,stroke,andchronicobstructiveairwaysdisease.
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patients survive for five years, and most patients are
treated palliatively from diagnosis. The difficulty and
discomfort of smoking cessation may mean that many
patients with advanced disease choose to continue
smoking. However, around 20% of patients present
early enough to be treated with curative intent (stage
I-IIIa non-small cell lung cancer, limited stage small
cell lung cancer) and have a relatively good
prognosis.
2 With improvements in treatment and
screening and the ageing population, this group of
patientsislikelytogrow.
10TheUKcancerreformstrat-
egy has called for improved services and support for
survivors of cancer generally,
11 and interventions to
support smoking cessation after diagnosis tailored to
the needs of lung cancer patients could be part of
these.
12 Such an intervention should be based on
robust evidence that quitting smoking actually
improves outcomes. We systematically reviewed the
literature to summarise the evidence for the effect of
quitting smoking after diagnosis of a primary lung
tumour on prognostic outcomes.
METHODS
We searched for randomised controlled trials or long-
itudinalobservationalstudiesinpatientswithlungcan-
cer, regardless of histology or stage at presentation,
thatmeasuredtheeffectofquittingsmokingafterdiag-
nosis on the risk of all cause mortality, cancer specific
mortality, development of a second primary tumour,
or recurrence. We searched CINAHL (from 1981),
Embase (from 1980), Medline (from 1966), Web of
Science (from 1966), and CENTRAL (from 1977) to
December 2008, using search strategies developed
with the support of an information specialist that
included exploded MeSH terms and also text words
relating to smoking and lung cancer. Because of the
large volume of studies identified from the search, we
separately used two types of filter for study design in
databases that returned a high number of studies.
Firstly, we filtered search returns for randomised
controlled trials in Medline and Web of Science by
using database specific filters. Secondly, we separately
filtered search returns for longitudinal observational
studies in Embase and Medline by using “prognosis-
specificity” database specific filters and in Web of
Science by using text words relating to the study
design. All searches were combined in a reference
manager database and duplicates removed. We also
searched the reference lists of included studies.
Two independent reviewers read titles, abstracts,
and full text papers and applied the inclusion criteria.
Two reviewers independently extracted data from
included full text papers. For each study, we extracted
data on baseline characteristics (age, sex, histology,
stage,grade,andsmokinghistory)ofthestudypopula-
tion that could potentially confound the link between
smokingandtheoutcome.Wealsoextractedthenum-
berofcontinuingsmokers,thenumberofquitters,and
the length of follow-up. We extracted survival out-
comes as hazard ratios with 95% confidence intervals.
If these were not presented, we followed methods
described by Parmar to extract them from Kaplan-
Meier curves, P values, or percentage survival (for
example, five year survival).
13 We contacted authors
if data were not presented in a useable form. In some
studies,observedriskwaspresentedasa proportionof
expected risk calculated by Poisson regression model-
ling with general population data. In these cases, we
calculated the hazard ratio by indirect comparison.
14
We combined extracted hazard ratios by using a ran-
dom effects inverse variance model in Stata. We com-
paredadjustedandunadjustedestimatesseparatelyfor
eachoutcomeinbothnon-smallcellandsmallcelllung
cancer, and we tested for statistical heterogeneity by
usingtheI
2test.PapersinlanguagesotherthanEnglish
were translated.
We assessed the quality of studies on the basis of a
framework proposed by Altman for the assessment of
prognostic studies.
15 Two points were available for
each of clarity of the inclusion criteria, controlling for
comorbidities, method of obtaining smoking data
(withanextrapointforbiochemicalvalidation),clarity
ofdefinitionofsmokingcategory,andlengthoffollow-
up, with a maximum score of 11.
Assuming that the findings of the review reflected a
causal relation between smoking cessation and risk of
all cause mortality, we further investigated the data by
constructing life tables for a hypothetical group of 100
patients aged 65 years with early stage lung cancer to
estimate how many deaths would be prevented by
smoking cessation within the non-small cell lung can-
cer and small cell lung cancer populations during five
years. We applied the average risk of death for contin-
ued smoking estimated from studies included in this
review that reported survival curves to estimate the
number of patients surviving after five years.
1617 We
estimated five year survival in quitters at diagnosis by
applying the death rate of continuing smokers multi-
plied by the reciprocal of the multivariate hazard ratio
for all cause mortality presented in this review.
Title search by two reviewers (n=6466)
Abstract search by two reviewers (n=1090)
Did not meet inclusion criteria (n=5376)
Did not meet inclusion criteria (n=822)
Full text search by two reviewers (n=268)
Compared risk in patients who continued
smoking with those who quit at diagnosis (n=10)
Untraceable by British Library (n=2)
Subsidiary papers (n=6)
Did not meet inclusion criteria (n=250)
Fig 1 | Flow of studies through trial
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seen in the survival of patients who stop smoking
might be a reduction in mortality from cardio-
respiratory causes, as the risk of death from these dis-
eases reduces after cessation.
918 Consequently, we
estimated the expected contribution of cardiovascular
andrespiratorydiseasesbyusinglifetablesasaboveto
findthenumberofcardiorespiratorydeathsprevented
by smoking cessation in the general population. We
estimated the risk of death due to cardiorespiratory
causes in the general population of 65-69 year olds
from data from the Office for National Statistics.
19
We assumed that this death rate was approximately
that of the non-smoking population, because around
12% of this age group smoke.
20 We multiplied this
ratebytherelativeriskofdeathfromcardiorespiratory
causes in lifelong smokers to estimate the number of
deaths that would be expected over five years from
cardiorespiratory causes in the general population of
65 year olds who smoke. We then applied the risk
reduction from cessation to estimate the number of
deaths that would be prevented and compared this
with those prevented in non-small cell lung cancer
and small cell lung cancer populations as estimated in
this review.
9
RESULTS
We did not identify any randomised controlled trials
testing the effect of smoking cessation on prognostic
outcomes in lung cancer. Also, in all studies identified
except one,
21 most of the patients presented with early
stage lung cancer and so the results reflect the possible
effect of smoking cessation in early stage lung cancer
onlyratherthaninadvanceddisease.Weobtainedfull
textarticlesfor268papers,fromwhichweincluded10
individual cohort studies in the review (fig 1).
Characteristics of included studies
A small proportion (10/268) of retrieved studies com-
pared the risk of developing outcomes of interest in
participants who continued smoking with that in
people who quit smoking around the time of
diagnosis.
161721-28 Of these, five studies estimated the
impact of continued smoking on all cause mortality
(four non-small cell lung cancer, two small cell lung
cancer), four studies looked at the development of sec-
ond primaries (one non-small cell lung cancer, three
smallcelllungcancer),andtwostudieslookedatrecur-
rence of the primary tumour (one non-small cell lung
cancer,onesmallcelllungcancer).Nostudiesreported
the impact of continued smoking on cancer specific
mortality. In eight studies that reported sex, most par-
ticipantswere male, rangingfrom 55% to 86%. All stu-
diesreportedstageofdisease;nineofthestudiesuseda
sample of patients of whom more than 75% presented
in potential curable early stages—that is, stage 1-3a
non-small cell lung cancer or limited stage small cell
lung cancer. Only one study reported tumour grade
(table 1).
25
Overall, scores for quality of studies ranged from 5 to
9 points out of a maximum of 11 points. Most studies
measured exposure to smoking retrospectively on the
basis of self report, and definitions of smoking status
were often not clear. Quality points were also lost
owing to lack of adequate control for comorbidities.
Patients were followed up for smoking status at six
months or longer in five studies,
1622232628 but smoking
was only measured at the time of diagnosis or treatment
in four studies,
17212427 and follow-up was not defined in
one study.
25 Two studies defined quitting as continuous
abstinence from within six months of starting treatment
to longest follow-up,
2223 and one study defined quitting
as continuous abstinence during and after treatment.
21
The remaining studies did not give a definition of
Table 1 |Characteristics of participants in included studies
Author (year) No in study*
No of
continuous
smokers†
No of
quitters†
Continuous
smokers (%)‡ Men (%)
Squamous cell
tumour (%)
Small cell lung
cancer (%)
Stage 1-3a/
limited (%) Grade 1-2 (%)
Non-small cell lung cancer studies
Baser (2006)
16 93 47 46 51 49 NR 0 90 NR
Kawaguchi (2006)
22 62 16 19 46 81 48 0 100 NR
Nia (2005)
17 311 169 35 83 86 47 0 92.1 NR
Saito-Nakaya
(2006)
24
238 6 92 6 60.9 21 0 81 NR
Shiba (2000)
25 156 8 61 12 72 59 0 100 72
Small cell lung cancer studies
Johnston-Early
(1980)
21
112 57 35 62 NR 0 100 29 NR
Kawahara (1998)
23 70 33 31 52 60 0 100 100 NR
Tucker (1997)
26 611 214 181 54 55 0 100 79 NR
Videtic (2003)
27 215 79 107 42 60 0 100 100 NR
Yoshida (1996)
28 61 26 33 44 80.3 0 100 85 NR
NR=not reported.
*Some studies also included former smokers and non-smokers, whose data were not included in meta-analyses presented here; characteristics of each study are for whole study population.
†See text for definition of smoking categories.
‡Continuous smokers/(continuous smokers+quitters)×100.
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232628 patientswere included in
the analysis if they had survived two years disease free,
and one study included only patients who had been dis-
ease free for three years (table 2).
22
Effect of quitting smoking at diagnosis on disease
progression and mortality
Non-small cell lung cancer
Four studies reported estimates of the association
between continued smoking and all cause mortality,
one study reported the association with occurrence of
a second primary tumour, and one study with recur-
rence in non-small cell lung cancer (fig 2). Estimates
were derived from samples in which at least 80% of
patients were diagnosed with a stage 1-3a tumour.
Unadjusted estimates suggested that continued smok-
ing was associated with an increased risk of all cause
mortalityof19%comparedwithquitters,althoughthis
wasnotsignificant.Oneofthefourstudiesreportedthe
association of baseline prognostic indicators with
smoking status and showed no significant difference
in distribution, suggesting limited confounding.
17
However, adjustment for key prognostic variables
resulted in an almost threefold increase in risk of all
cause mortality for continuing smokers (hazard ratio
2.94, 95% confidence interval 1.15 to 7.54). After
adjustment, we found no significant increase in the
occurrence of second primaries (hazard ratio 2.29,
0.50 to 10.58); however, one study reported an almost
twofold increase in risk of recurrence for continuing
smokers (1.86, 1.01 to 3.41).
Small cell lung cancer
All cause mortality in continued smokers withsmall cell
lung cancer was significantly increased before and after
adjustment,andadjustmentstrengthenedtheassociation
(unadjusted hazard ratio 1.18, 1.03 to 1.36; adjusted
hazard ratio 1.86, 1.33 to 2.59) (fig 3). Estimates were
derived from populations in which at least 79% of
patients were diagnosed with limited stage disease,
apartfromonestudyinwhich29%ofpatientspresented
with limited stage disease. We found no heterogeneity
between unadjusted scores despite a marked difference
betweenthepopulationsintermsofstageatpresentation
(table 1). Unadjusted estimates suggested an 86%
increase in risk of developing a secondprimary tumour,
which was strengthened after adjustment to a fourfold
increase in risk for continuing smokers over those who
quit at diagnosis (hazard ratio 4.31, 1.09 to 16.98),
although confidence intervals were wide. One study
reported an unadjusted estimate for the association
between continued smoking on recurrence that was sta-
tistically significant (hazard ratio 1.26, 1.06 to 1.50).
Baseline characteristics for this study were presented
by smoking group and were distributed equally apart
from a significantly higher proportion of women in the
group that continued smoking.
Contribution of cardiovascular and respiratory mortality
to reduced mortality
Thelifetableanalysiswasbasedonanotionalcohortof
65 year old smokers diagnosed with early stage non-
small cell lung cancer or limited stage small cell lung
cancer. Assuming a causal relation between smoking
cessation and all cause mortality, the estimated five
year survival rates were 33% in continuing smokers
and 70% in quitters for non-small cell lung cancer
and 29% in continuing smokers and 63% in quitters
for small cell lung cancer. In life table analyses based
on data for the general population, five year survival
from cardiorespiratory deaths was estimated at 93% in
smokers and 95% in quitters.
DISCUSSION
We reviewed 10 observational studies, all of which
showed some evidence that people who continue to
Table 2 |Methodological characteristics of included studies and quality score
Author (year)
Prospective (1)/
retrospective (2)
Exposure follow-
up* (maximum)
Method of outcome
measurement
Outcome
follow-up*
(years)
(maximum)
Outcomes
measured Treatment†
Study
quality score
Non-small cell lung cancer studies
Baser (2006)
16 1 1 year Self report, case notes 5+ ACM Mixed 9
Kawaguchi (2006)
22 2 3 years Self report, questionnaire‡ 12.2 SP Mixed 8
Nia (2005)
17 2 Unclear Self report, questionnaire 11.25 ACM, REC Mixed 7
Saito-Nakaya (2006)
24 1 1 month Self report, case notes 7.6 ACM Surgery 7
Shiba (2000)
25 1 Unclear Self report, case notes 5+ ACM Surgery 5
Small cell lung cancer studies
Johnston-Early (1980)
21 Unclear After treatment Self report, verbal 4 ACM Chemotherapy/radiotherapy 6
Kawahara (1998)
23 2 2 years Self report, verbal† 10+ SP Chemotherapy/radiotherapy 8
Tucker (1997)
26 2 2 years Self report, case notes 10+ SP Chemotherapy/radiotherapy 7
Videtic (2003)
27 2 Start of treatment Self report, case notes 7 ACM, REC Chemotherapy/radiotherapy 5
Yoshida (1996)
28 1 2 years Self report, case notes/verbal† 10+ SP Chemotherapy/radiotherapy 8
ACM=all cause mortality; REC=recurrence; SP=second primary.
*Last point at which exposure data and outcome data were measured from beginning of study.
†Mixed=combination of surgery and chemotherapy/radiotherapy or both.
‡Questionnaire or verbal follow-up completed by patients still alive at time of maximum follow-up or by relatives.
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an associated higher risk of recurrence, second pri-
mary tumour, or all cause mortality compared with
those who stop smoking at that time. Although unad-
justed estimates suggest that the associated increase in
riskofcontinuing(orthebenefitofcessation)ismodest
at around 20%, the adjusted estimates suggest a more
than doubling of the risk of death from continued
smoking.Inbothearlystagenon-smallcelllungcancer
and limited stage small cell lung cancer, we found evi-
dence of a significant association between continued
smokingandrecurrenceoftheprimarytumour;inlim-
ited stage small cell lung cancer, we found also evi-
dence of a substantial elevation in the incidence of a
second primary tumour. These elevated risks were
apparent within seven years of diagnosis. In a life
table model, assuming that these observations arose
fromacausalrelation,weestimatedthebenefitsofces-
sation to be substantial; the benefits on all cause mor-
tality seem likely to be mainly due to reduced
progressionofcancerratherthanpreventionofcardio-
respiratorydisease,butnostudiesreportedcancerspe-
cific death rates to confirm this.
Strengths and limitations of study
An important strength of this study is the exhaustive
search for relevant studies. Five of the 10 studies were
ostensibly about the relation of other potential prog-
nostic variables to outcomes but happened to present
data on smoking status as a potential confounder of
those relations. Such a strategy mitigates concern
about publication bias because the decision to publish
was unrelated to the findings on smoking status and
cancer outcome.
We did this review to find evidence that smoking
cessation improves prognostic outcomes in patients
with lung cancer, but in the absence of data from ran-
domised controlled trials no causal inferences can be
made. This is the most important limitation of the
study.Also,onlyonestudyreportedontheassociation
of smoking cessation and prognosis in a sample of
patients presenting in mainly advanced disease, so
theimplicationofthesefindingsthatsmokingcessation
is beneficial applies only to patients with early disease.
A major challenge with systematic reviews of obser-
vational studies is the possibility of uncontrolled con-
founding. Four of the 10 included studies presented
data on the baseline distribution of potential confoun-
ders split by quitting status.
16172127 Two studies found
an uneven distribution of baseline factors
1617; the
group that stopped smoking contained a higher pro-
portion of male patients in both studies and more
patients with a history of cancer in one study. If, in
general, potential confounding variables were not
associated with quitting status, the ratio of unadjusted
to adjusted hazard ratios within studies should be ran-
domly distributed about one. For those studies that
presented unadjusted and adjusted hazard ratios,
theseratioswerelowerthanone,andmultivariateana-
lysis showed a strengthened effect.
172327 This suggests
that smokers with unfavourable prognostic factors
were the most likely to give up smoking, so that
unadjusted estimates underestimated the benefits of
quitting.
Weassessedqualityonthebasisofcriteriaproposed
by Altman,
15 and we found studies to be of moderate
quality with between 44% and 67% of the total avail-
able score. Definitions of smoking abstinence were
generallypoor,andonlyfiveofthe10studiesassigned
patients to smoking categories on the basis of smoking
status recorded at six months or more after diagnosis.
Future studies in this area need to use accepted stan-
dards for measurement of smoking abstinence.
29
Comparison with previous studies
No previously published systematic reviews have esti-
mated the effect of smoking cessation on prognosis
afteradiagnosisoflungcancer.However,thisquestion
has been investigated for other cancers. A systematic
reviewofobservationalstudiessuggestedthatsmoking
cessation after bladder cancer is beneficial, but owing
to confounding and methodological concerns of
included studies no firm conclusions could be
drawn.
30 Some observational studies have also shown
an association between smoking cessation in patients
with head and neck cancer and reduced risk of disease
progression and mortality, but the absence of a sys-
tematic review and meta-analysis means that the
strength of this association is uncertain.
31-33
Our review also collected data on rates of post-
diagnosis smoking cessation. Reports in the literature
oftheproportionofpatientswithlungcancerwhocon-
tinuetosmokeafterdiagnosisareconflicting,withesti-
mates ranging from 13% to 60%.
34-36 Variation in
reported rates may be due to differences in the clinical
All cause mortality (unadjusted)
  Saito-Nakaya 200624
  Nia 2005
17
  Shiba 2000
25
  Baser 2006
16
Subtotal (I
2=0.0%, P=0.745)
All cause mortality (adjusted)
  Nia 2005*17
Second primary (unadjusted)
  Kawaguchi 200622
Second primary (adjusted)
  Kawaguchi 2006†22
Recurrence (adjusted)
  Nia 2005*17
2.20 (0.48 to 10.16)
1.93 (0.51 to 7.34)
1.15 (0.26 to 5.10)
1.14 (0.87 to 1.50)
1.19 (0.91 to 1.54)
2.94 (1.15 to 7.54)
2.94 (1.15 to 7.54)
0.35 (0.06 to 2.06)
0.35 (0.06 to 2.06)
2.29 (0.50 to 10.58)
2.29 (0.50 to 10.58)
1.86 (1.01 to 3.41)
1.86 (1.01 to 3.41)
2.91
3.82
3.06
90.21
100.00
0.1 0.2 0.5 1 25 10
Hazard ratio
(95% CI)
Hazard ratio
(95% CI)
Weight
(%)
98
204
69
93
204
35
35
204
No
Fig 2 | Effect of continued smoking on all cause mortality and recurrence in non-small cell lung
cancer. Weights are from random effects analysis. *Adjusted for age, sex, type of operation,
histology, postoperative radiotherapy, N status, T status, and previous malignancies.
†Adjusted for sex, histology, and cumulative smoking
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ment, and methods of measuring smoking
abstinence.
37Instudiesincludedinthisreview,thepro-
portionofcurrentsmokersatdiagnosiswhocontinued
tosmokerangedfrom6%to83%.Reasonsforthishet-
erogeneity may be that some studies collected data on
smoking status retrospectively, that no studies used
biochemical confirmation, and that some studies mea-
suredonlychangeinsmokingstatusatthetimeofdiag-
nosis or treatment without follow-up measurements.
This may have mixed the true exposure status, which
is likely to have underestimated the benefits of cessa-
tion as quitters are more likely to relapse.
38
Possible explanations for findings
Assuming that the association between smoking cessa-
tion and risk of all cause mortality represents a causal
relation and is not due to bias or confounding, at least
twopossibleexplanationsexist.Firstly,smokingcessa-
tion may decrease the risk of death due to other smok-
ing related causes such as cardiorespiratory diseases.
Secondly, smoking cessation might decrease the risk
of disease progression and death.
Life table modelling showed that the reduction in
cardiorespiratory deaths that might be expected in
the general population from smoking cessation
increased five year survival by 2% in absolute terms,
whereassmokingcessationafterthediagnosisofearly
stage non-small cell lung cancer and limited stage
small cell lung cancer increased five year survival by
37% and 34%. This exercise was based on assump-
tions that are likely to underestimate the possible
mortality benefit from smoking cessation. For the
65-69 year old general population, the baseline esti-
mate of cardiorespiratory death rate was based on an
assumption that the population were non-smokers;
however, although the prevalence of smoking is
only around 12%, many will be ex-smokers, confer-
ring a baseline risk greater than that of a completely
non-smoking population, which would overestimate
the reduction from cardiorespiratory causes. On the
other hand, the higher prevalence of pre-existing
cardiorespiratorydiseasein patientswith lung cancer
means that the absolute mortality gains seen in a gen-
eralpopulationare probablylower than thoseinlung
cancer patients.
39 Neither assumption seems suffi-
ciently inaccurate to challenge the data suggesting
that the major benefit from smoking cessation would
be conferred by a reduction in cancer specific risk, if
the reduced risk seen in this review was caused by
smoking cessation.
The risk of cardiovascular related illness and death
is known to decrease after smoking cessation in
patients with coronary heart disease,
40 reducing dra-
matically over the first three years,
41 but reducing the
risk of developing lung cancer after smoking cessa-
tion generally takes longer.
941This review has found
evidence that after lung cancer has been diagnosed,
reductions in risk of developing a second primary or
recurrencewereassociatedwithquittingwithinseven
years, suggesting that, even at this stage, the prognos-
tic outlook can be improved by smoking cessation.
Whether components of tobacco smoke affect the
progression of lung cancer is currently not known,
although a recent review suggests that tobacco
derived carcinogens such as aromatic hydrocarbon
compounds may induce cellular changes that pro-
gress the disease.
7 Another possibility is that nicotine
m i g h th a v ear o l ei na n g i o g e n e s i sa n dt h e r e f o r ep r o -
mote tumour growth.
4243 The findings of our review
supportthehypothesisthatcontinuedsmokingaffects
the behaviour of a lung tumour. Establishing the role
of cigarette smoke in progression of cancer will not
only produce the necessary evidence for implement-
ing smoking cessation interventions but may also
help to identify cellular mechanisms for therapeutic
targeting.
All cause mortality (unadjusted)
  Johnston-Early  198021
  Videtic 2003
27
Subtotal (I
2=0.0%, P=0.906)
All cause mortality (adjusted)
  Videtic 2003*27
Second primary (unadjusted)
  Kawahara 199823
  Tucker 199726
  Yoshida 1996
28
Subtotal (I
2=0.0%, P=0.775)
Second primary (adjusted)
  Kawahara 1998†
23
Recurrence (adjusted)
  Videtic 2003*27
1.16 (0.87 to 1.56)
1.19 (1.01 to 1.39)
1.18 (1.03 to 1.36)
1.86 (1.33 to 2.59)
1.86 (1.33 to 2.59)
3.39 (0.56 to 20.56)
1.72 (0.83 to 3.54)
1.34 (0.05 to 35.97)
1.86 (0.96 to 3.60)
4.31 (1.09 to 16.98)
4.31 (1.09 to 16.98)
1.26 (1.06 to 1.50)
1.26 (1.06 to 1.50)
22.15
77.85
100.00
13.36
82.63
4.01
100.00
0.1 0.2 0.5 1 25 10
Hazard ratio
(95% CI)
Hazard ratio
(95% CI)
Weight
(%)
92
186
186
64
395
59
64
186
No
Fig 3 | Effect of continued smoking on all cause mortality, development of a second primary, or
recurrence in small cell lung cancer. Weights are from random effects analysis. *Adjusted for
sex, age, and volume of limited disease. †Adjusted for sex, age, performance status,
etoposide, radiotherapy, and cumulative smoking
WHAT IS ALREADY KNOWN ON THIS TOPIC
Smoking increases the risk of developing a primary lung
cancer; lifelong smokers have a 20-fold increased risk
compared with non-smokers
Whether stopping smoking after a diagnosis of lung cancer
improves outcomes is not known
WHAT THIS STUDY ADDS
For early stage lung cancers, smoking cessation is
associated with a substantial reduction in the risk of death
Life table modelling indicates that most of the benefit from
smoking cessation is due to a reduced likelihood of cancer
progression rather than a reduction in cardiorespiratory
deaths
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The UK cancer reform strategy has underlined the
need for rehabilitative care of survivors of cancer to
reduce the risk of disease progression and improve
quality of life.
11 These data provide a strong case that
smoking cessation treatment for early stage lung can-
cerpatientswhohavebeenunabletoquitmayhavean
important role in secondary prevention. Such a pro-
gramme should be based on evidence that quitting
smoking is causally related to improved outcomes
and that smoking cessation interventions in this
grouparecosteffective.Thisreviewprovidessufficient
evidence to support a randomised trial to examine
these questions.
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